impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis

1, 2, 3, 4, 5, 6, 7, 8

 

  1. Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany.
  2. Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany.
  3. Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany.
  4. Biostatistics, GKM Gesellschaft für Therapieforschung mbH, München, Germany.
  5. J.-W. Goethe-University of Frankfurt, Frankfurt am Main, Germany.
  6. AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
  7. AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
  8. Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany..

CER7329
2015 Vol.33, N°3
PI 0321, PF 0329
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 25897681 [PubMed]

Received: 11/02/2014
Accepted : 22/09/2014
In Press: 14/04/2015
Published: 22/06/2015

Abstract

OBJECTIVES:
The aim of this study is to use data from a non-interventional study of adalimumab in patients with rheumatoid arthritis (RA) during routine clinical practice to evaluate the impact of prior treatment with biologics on the effectiveness of current therapy.
METHODS:
Efficacy parameters were evaluated for all patients with values at baseline and month 12. Subgroup analyses were performed on patients with 0, 1, or ≥2 prior biologic agents. Key outcome measures included Disease Activity Score- 28 joints (DAS28) and Funktionsfragebogen Hannover (FFbH) functional ability score.
RESULTS:
A total of 4700 RA adalimumab-treated patients were included in this analysis. Baseline disease activity increased with an increasing number of prior biologic agents and therapeutic response diminished. After 12 months of adalimumab therapy, DAS28 and FFbH scores showed improvements in all groups, but the group with 0 prior biologic agents had the best outcomes, while the group with ≥2 prior biologic agents had the worst. Clinical response (EULAR and DAS28-dcrit) and remission rates showed a similar pattern. Nevertheless, 44% to 67% of patients treated with ≥2 prior biologic agents achieved a clinical response. Multiple regression analyses identified prior biologic therapy as a significant negative predictor for response to therapy.
CONCLUSIONS:
Treatment with adalimumab leads to decreases in disease activity and improvements in function. Improvements are most pronounced in patients with 0 or 1 prior biologic agent, but a substantial proportion of patients treated with ≥2 prior biologic agents experience significant benefit from adalimumab therapy.

Rheumatology Article